Endocrine Abstracts

Obesity is due to the combined effects of genetic, environmental, lifestyle and the interactions of these factors. Leptin (LEP) is an adipocyte-derived hormone that acts to reduce food intake and increase energy expenditure by binding and activating its specific receptor in the hypothalamus. In humans, LEP and LEPR have been mapped to 7q31.3 and lp31, respectively. The LEP and LEPR genes have been investigated in the search for gene variants potentially related to the pathophysiology of obesity in diabetes and its associated complication. In this study, we were investigated LEP gene G-2548A and LEPR gene 668A>G (Q223R) polymorphisms and its association with obesity in Tokat district particular subjects. The study group comprised to 112 obese patients (81 female, 31 male, mean BMI 35.41 kg/m²) ages from 18 to 82 (mean age; 50±14.25 year), and 105 non-obese healthy subjects (62 female, 43 male, mean age 34.25±15.44 year, and mean BMI 21.57 kg/m²) were used the control group in this study. The obtained results showed that, there is no significant differences for allele and genotype distributions of LEP gene G-2548A and LEPR gene 668A>G (Q223R) polymorphisms between obese and control subjects (P>0.05). In the comparison between BMI >35 and BMI <35 obese groups we were obtained significantly difference for GG genotype for LEP gene G-2548A polymorphisms (P=0.034). This results shows that GG genotype for LEP gene G-25248A polymorphism maybe predisposed to morbid obese. There was a significant difference in LEP and LEPR double GG-GG (RR) genotype for frequency when comparing obese (BMI >35) and control subjects (P=0.015). According to these results, we thinking that, LEP gene G-2548A and LEPR gene 668A>G (Q223R) polymorphisms may be effective on the obesity in Turkish population.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.